Observational analysis revealed high mortality and attrition during treatment in metastatic non-small cell lung cancer, indicating management challenges.
Despite incorporating PD-(L)1-based therapies for frontline mNSCLC, mortality and attrition during LOT1 remained high and therapy duration was short, reflecting challenges in managing mNSCLC.
No takes yet. Share an insight, caveat, or question.
Schoenfeld et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: